Search Results for "Inflammatory Bowel Disease"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Inflammatory Bowel Disease. Results 11 to 20 of 90 total matches.
Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea ...
The FDA has approved eluxadoline (Viberzi – Actavis),
a mu-opioid receptor agonist and delta-opioid
receptor antagonist, for oral treatment of adults with
irritable bowel syndrome with diarrhea (IBS-D).
Alosetron (Lotronex) For Treatment of Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Jun 26, 2000 (Issue 1081)
for treatment of irritable bowel syndrome (IBS) in women
whose primary bowel symptom is diarrhea.
THE DISORDER ...
Alosetron hydrochloride (Lotronex - Glaxo Welcome), a selective serotonin receptor antagonist, has received FDA approval for treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is diarrhea.
Tegaserod Maleate (Zelnorm) for IBS with Constipation
The Medical Letter on Drugs and Therapeutics • Sep 16, 2002 (Issue 1139)
for short-term treatment of women with irritable bowel syndrome (IBS)
whose primary symptom is constipation ...
Tegaserod maleate (teg a ser' od; Zelnorm - Novartis), a serotonin derivative, has received FDA approval for short-term treatment of women with irritable bowel syndrome (IBS) whose primary symptom is constipation. Alosetron (Lotronex), which was withdrawn previously because of toxicity, will soon be available again for women with severe diarrhea-predominant IBS (Medical Letter 2002; 44:67).
Table: Safety of Drugs for IBD in Pregnancy (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
inhibitors risankizumab Crohn's disease vedolizumab inflammatory bowel disease ustekinumab Asacol ulcerative ...
View the Table: Safety of Drugs for IBD in Pregnancy
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e113 doi:10.58347/tml.2023.1680b | Show Introduction Hide Introduction
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only) ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Table: Some Drug Interactions with Drugs for IBD (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
inflammatory bowel disease Crohn's disease aminosalicylates vedolizumab sulfasalazine azathioprine tofacitinib ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114 doi:10.58347/tml.2023.1680c | Show Introduction Hide Introduction
Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
. Irritable bowel syndrome in pregnancy. Am J Gastroenterol 2021; 116:480.
2. Lactmed. Available at: https ...
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2 doi:10.58347/tml.2025.1721b | Show Introduction Hide Introduction
Linaclotide (Linzess) for Constipation
The Medical Letter on Drugs and Therapeutics • Nov 12, 2012 (Issue 1403)
by the FDA for oral treatment of chronic idiopathic
constipation (CIC) and irritable bowel syndrome ...
Linaclotide (lin´´ a kloe´ tide; Linzess – Ironwood/Forest),
a guanylate cyclase-C receptor agonist, was recently
approved by the FDA for oral treatment of chronic idiopathic
constipation (CIC) and irritable bowel syndrome
with constipation (IBS-C) in adults. It is the second drug
approved for this indication; lubiprostone (Amitiza), a
metabolite of prostaglandin E1, was the first.
In Brief: Pancreatitis with Eluxadoline (Viberzi) in Patients without a Gallbladder
The Medical Letter on Drugs and Therapeutics • Apr 24, 2017 (Issue 1519)
in 2015 for treatment of irritable
bowel syndrome with diarrhea (IBS-D),1 should not be used
in patients ...
The FDA has warned that eluxadoline (Viberzi – Allergan), a mu-opioid receptor agonist and delta-opioid receptor antagonist approved in 2015 for treatment of irritable bowel syndrome with diarrhea (IBS-D),1 should not be used in patients without a gallbladder because of an increased risk of serious pancreatitis.2As of February 2017, the FDA had received reports of 118 cases of serious, nonfatal pancreatitis and 2 deaths associated with use of eluxadoline. Both deaths occurred in patients without a gallbladder who developed severe abdominal pain and vomiting shortly after taking the first...
In Brief: Tegaserod (Zelnorm) Returns
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
treatment
of irritable bowel syndrome with constipation (IBS-C) in
women and in 2004 for treatment ...
Tegaserod maleate (Zelnorm), a 5-HT4 receptor partial agonist that increases gastrointestinal (GI) motility, was approved by the FDA in 2002 for short-term treatment of irritable bowel syndrome with constipation (IBS-C) in women and in 2004 for treatment of chronic idiopathic constipation (CIC) in adults <65 years old.In 2007, the manufacturer (Novartis) complied with an FDA request to stop marketing the drug based on an unpublished retrospective analysis of clinical trials in IBS-C and other GI motility disorders that showed a higher rate of ischemic cardiovascular events (including...